
Structural Heart Disease Device Developer
Recently, Jiangsu Trulive Medtech Co., Ltd. independently developed the peripheral intravascular shock wave system —— DEEPQUAKE™ (China Medical Device Registration No. 20243012326;(China NMPA Registration No. 20243012335) has been reviewed and approved by the National Medical Products Administration (NMPA),Officially Approved for Marketing!

Lower Extremity Arterial Calcific Lesions: A Challenge in Clinical PAD Treatment
DEEPQUAKE™, as one of the first domestically produced peripheral vascular intravascular shockwave systems to be launched in China,The application of IVL technology on intimal and medial arterial calcification has demonstrated good efficacy and safety in clinical studies. The product offers greater pulse energy, multiple electrode arrangements, and a variety of balloon lengths, providing more treatment options. It can be used for the pretreatment and balloon dilation of calcified lesions (vascular stenosis ≥50%) in the iliac, femoral, iliofemoral, popliteal, renal, and infrapopliteal arteries of adult patients.
· Larger pulse energy
DEEPQUAKE™ IVL offers five adjustable energy levels. For mild calcification, low-level energy output is selected, while for severe calcification, high-level energy output is chosen. In pre-market clinical trials, approximately 20% of enrolled patients who showed poor response to level 3 energy treatment were successfully treated after upgrading to level 5. Additionally, about 4% of patients who did not respond well to level 4 energy treatment also achieved the desired outcome after escalating to level 5. DEEPQUAKE™ IVL provides more options to enhance the treatment efficiency of severe calcified lesions.
· A larger number of electrodes
DEEPQUAKE™ IVL Balloon with up to 8 electrodes emits shockwaves to calcified lesions from different positions, ensuring uniform energy release, increasing the probability and number of micro-cracks, and enhancing treatment effectiveness; meanwhile, multiple electrodes disperse energy output, reducing localized vascular wall injury. Moreover, DEEPQUAKE™ balloon expansion for long lesions does not require overlapping, alignment of the balloon marker bands is sufficient. DEEPQUAKE™ IVL, with a higher number of electrodes, releases energy uniformly and dispersively to improve its safety and efficacy.
· Longer balloon length
DEEPQUAKE™ IVL offers an 80 mm long balloon to accommodate long lesions, shorten procedure time, and reduce the number of IVL treatments; it saves pulse emissions when treating lesions of the same length, providing convenience for the treatment of long lesions.
Trulive's DEEPQUAKE™ Peripheral Intravascular Shockwave System is a significant breakthrough in the localization of intravascular shockwave technology in China.The approval and market launch of this product will further promote the localization process of products in the field of vascular calcification interventional treatment, expanding and fulfilling the treatment options for a large number of patients with vascular calcification. In the future, Trulive will continue to innovate and develop, constantly providing more safe and effective innovative solutions for patients with cardiovascular diseases, allowing "Chinese wisdom" to serve the world!
-End-
Trulive
Jiangsu Trulive Medtech Co., Ltd. is a leading cardiovascular intervention platform company in China. The company focuses on cardiovascular disease areas with extremely high mortality and disability rates, where domestically produced products are still lacking. Its business comprehensively covers four major disease areas: heart valves, heart failure, peripheral, and coronary diseases, making it the first domestic platform-based high-end medical device company to fully cover these four key sectors with substantial progress achieved in core products. With strong research and development capabilities and an experienced, complete operational team, Trulive Medtech has developed high-quality, proprietary medical devices and comprehensive solutions with independent intellectual property rights, filling the gap in China’s high-end vascular intervention medical device market. It provides Chinese doctors and patients with more advanced and diverse treatment options, offering "Chinese solutions" and contributing "Chinese wisdom" in many细分 markets within the cardiovascular intervention field that have long been monopolized by imported products.

Scan the QR code to follow us
Business Cooperation | 021-50625001-8930
Email Address | vicky.z@trulive.cn